BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero Therapeutics (SPRO)Spero TherapeuticsEarnings

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025

In February, Spero's licensing partner, GSK announced the FDA had set the PDUFA date as June 18, 2026

Spero...

Open original release

Related news

SPROSpero Therapeutics2025-03-27 16:01 EST

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

SPROSpero Therapeutics2024-03-13 15:01 EST

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

VIRIVirios Therapeutics2026-03-18 12:30 EST

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

ANTXAN2 Therapeutics2026-03-17 20:00 EST

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AVIRAtea2026-02-26 12:00 EST

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

ABUSArbutus2026-03-23 11:30 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

AVIRAtea2026-03-05 21:05 EST

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

VIRIVirios Therapeutics2026-05-14 12:30 EST

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

View all latest news

Spero Therapeutics

Spero Therapeutics is an anti-infective company focused on bacterial infections and novel antibiotics. Its story is centered on addressing drug-resistant pathogens and difficult infection settings.

Recent company news

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

SPROSpero Therapeutics2026-05-13 16:05 EST

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-05-05 16:05 EST

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

SPROSpero Therapeutics2026-03-26 16:05 EST

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Stock data

Close
1.18 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States